Connect with us


Brain health supplement market set for boost



The market for brain supplements is expected to grow by US $4,020.62m in the next four years – driven largely by an ageing global population.

Thriving urban communities and a rise in the number of retail sales outlets, are also expected to help push up the compound annual growth rate (CAGR) by 8.18% between now and 2027, according to the latest industry analysis from market research company, Technavio.

But it is the world’s geriatric population, who are more prone to age-related cognitive diseases, that are expected to be the main market driver in the coming years.

In 1965 there were 129 million over-65s across the globe. Today that figure has swelled to nearly 750 million. Population ageing is now the major global demographic trend, with the number of over 65s projected to hit 1.5 billion by 2050.

For the first time in history, in 2018 the number of persons aged 65 and over outnumbered children under five years of age globally.

Increased longevity has brought with it a host of health problems, however. The longer people live the more likely they are to develop chronic illnesses like cancer, dementia, cardiovascular disease, obesity and type 2 diabetes, and to suffer from serious mobility issues.

This has led to a boom in the health supplements market in general amongst this age group. A recent government study conducted in the US found that 80.2% of both men and women aged over 60 were taking health supplements.

Amongst the most popular were brain supplements, both prescribed and purchased, to help reduce the risk of cognitive decline. Research at Oxford has found that, in normal people, the level of vitamin B12 in the blood is related to the rate at which the brain shrinks.

The brain naturally shrinks as we age, but in the study people with low to normal levels of B12 showed more rapid wastage.

The Oxford study showed that those with mild cognitive impairment benefitted from a B vitamin mixture. It was vitamin B12 that turned out to be of most benefit.

The beneficial effects 0f B vitamins on the brain were enhanced in people with good omega-3 levels, the Oxford work found.

The Technavio analysis says it is the consumption of some of the most common brain supplements, including the B vitamins, omega-3 fatty acids, ginkgo biloba, bacopa monnieri, caffeine, and acetyl-L-carnitine, among others that are driving the growth of the segment.

North America is predicted to account for 41% of the market growth between now and 2027.

The report says: “ The growth of the regional market can be attributed to various factors including the rising awareness of brain health, rapid urbanisation, and the increased availability of brain health supplements through online channels. In addition, the presence of prominent vendors and the growing geriatric population drive the brain health supplements market in North America.”

Technavio acknowledges that the market is fragmented and recognises that the low penetration in developing countries is likely to hinder growth.

The report says: “The popularity of brain health supplements in developing countries is comparatively lower than in developed countries. The low purchasing power, lower awareness, and poor distribution channels have reduced the penetration of brain health supplements. 

“However, the number of awareness programmes regarding these products is on the rise in developing countries. But the high price of these supplements restricts their adoption in such regions. All these factors reduce the growth potential of the market.”


Tai chi outperforms conventional exercise for seniors



New findings from 12 studies involving 2,901 participants have demonstrated that tai chi outperforms conventional exercise in improving mobility and balance in seniors.

While tai chi is understood to be beneficial for functional mobility and balance in older adults, such benefits are not well understood due to large variance in research study protocols and observations.

This new review and analysis has now shown that tai chi can induce greater improvement in functional mobility and balance in relatively healthy older adults compared to conventional exercise.

The findings showed the following performance results:

  • The time to complete 50-foot walking was 1.84 seconds faster. 
  • The time to maintain a one-leg stance was 6 seconds longer when eyes were open and 1.65 seconds longer when eyes were closed. 
  • Individuals improved their timed-up-and-go test performance by 0.18 points, indicating quicker standing, walking, and sitting.
  • Individuals taking the functional reach test showed significant improvement with a standardised mean difference of 0.7, suggesting a noteworthy positive impact on the ability to reach and perform daily activities.

Secondary analyses revealed that the use of tai chi with relatively short duration of less than 20 weeks, low total time of less than 24 total hours, and/or focusing on the Yang-style of this ancient form of Chinese martial arts were particularly beneficial for functional mobility and balance as compared to conventional exercise.

“This systematic literature review and meta-analysis are exciting because they provide strong evidence that tai chi is a more efficient strategy to improve functional mobility and balance in relatively healthy older adults, as compared to conventional exercise,” said Brad Manor, Ph.D., director of the Mobility and Falls Program at Hebrew SeniorLife’s Hinda and Arthur Marcus Institute for Aging Research, and associate professor of medicine, Harvard Medical School and Beth Israel Deaconess Medical Center.

“This research suggests that tai chi should be carefully considered in future studies and routines of rehabilitative programs for balance and mobility in older adults,” said Bao Dapeng, professor at Beijing Sport University.

Continue Reading


New standards for biomarkers of ageing



A paper has put forward a new framework for standardising the development and validation of biomarkers of ageing to better predict longevity and quality of life.

Led by Harvard researchers, the team has zeroed in on biomarkers of ageing using omic data from population-based studies. 

The team included ageing and longevity expert Alex Zhavoronkov, PhD, founder and CEO of AI-driven drug discovery company Insilico Medicine, and the findings appeared in Nature Medicine

Ageing is associated with a number of biological changes including increased molecular and cellular damage, however, researchers do not yet have a standardised means to evaluate and validate biomarkers related to ageing. 

In order to create those standards as well as actionable clinical tools, the team analysed population-based cohort studies built on omic data (data related to biological molecules which can include proteomics, transcriptomics, genomics, and epigenomics) of blood-based biomarkers of ageing. The researchers then compared the predictive strength of different biomarkers, including study design and data collection approaches, and looked at how these biomarkers presented in different populations. 

In order to better assess the impact of ageing using biomarkers, the researchers found that clinicians needed to expand their focus to consider not only mortality as an outcome, but also how biomarkers of aging are associated with numerous other health outcomes, including functional decline, frailty, chronic disease, and disability. They also call for the standardisation of omic data to improve reliability. 

“Omics and biomarkers harmonisation efforts, such as the Biolearn project, are instrumental in validation of biomarkers of aging” said co-first author Mahdi Moqri, PhD, of the Division of Genetics. 

Biolearn is an open-source project for biomarkers of aging and is helping to harmonise existing ageing biomarkers, unify public datasets, and provide computational methodologies.

The team also emphasised the importance of continued collaborations among research groups on “large-scale, longitudinal studies that can track long-term physiological changes and responses to therapeutics in diverse populations”, and that further work is required to understand how implementation of biomarker evaluation in clinical trials might improve patient quality of life and survival.

“If we hope to have clinical trials for interventions that extend healthy lifespan in humans, we need reliable, validated biomarkers of ageing,” said co-first author Jesse Poganik, PhD, of the Division of Genetics. 

“We hope that our framework will help prioritise the most promising biomarkers and provide health care providers with clinically valuable and actionable tools.”

Continue Reading


Healthy aging research to receive $115 million



Global non-profit Hevolution Foundation has announced $115 million in funding that makes up 49 new awards under its Geroscience Research Opportunities (HF-GRO) programme.  

As part of Hevolution’s mission to catalyse the healthspan scientific ecosystem and drive transformative breakthroughs in healthy aging, HF-GRO is funding promising pre-clinical research in aging biology and geroscience. 

Through this first wave of HF-GRO awards, Hevolution will invest up to $115 million in this first cohort of 49 selected projects over the next five years. Its second call for proposals under HF-GRO will be announced later this year, offering an additional $115 million to address the significant funding gaps in aging research.  

Dr. Felipe Sierra, Hevolution’s Chief Scientific Officer stated: “These 49 important research projects represent a significant step forward in deepening our understanding of healthy aging. Hevolution’s prime objective is to mobilise greater investment around uncovering the foundational mechanisms behind biological aging. 

“We are steadfast in our belief that by examining the root causes of aging, rather than solely focusing on its associated diseases, we can usher in a brighter future for humanity.” 

HF-GRO awardees include researchers at prestigious institutions across the United States, Canada, and Europe, including the U.S. National Institute on Aging, Brigham and Women’s Hospital, the Buck Institute, the Mayo Clinic, New York University, and the University of California San Francisco, among many others. 

The American Federation for Aging Research is providing programmatic support for the HF-GRO program, with grantees selected through a rigorous two-stage peer-review process involving 100 experts in aging biology and geroscience. 

Dr Berenice Benayoun, an HF-GRO grant recipient at the University of Southern California, stated: “I am extremely honored and excited that Hevolution selected our project for funding. This is a project close to my heart, which aims at understanding why and how the female and male innate immune aging differs. 

“This funding will support us as we start laying the foundation for a lasting improvement of women’s health throughout aging.” 

To date, Hevolution has committed approximately $250 million to transform the healthy aging sector, including the $40 million for specialised research and development in healthspan science recently announced at Hevolution’s Global Healthspan Summit. 

Hevolution is ramping up its investments to enable healthier aging for all and is now the second largest funder of aging biology research worldwide.  

Continue Reading